Approaches to therapy of the metabolic phenotype of osteoarthritis: efficacy of a combination of glucosamine and chondroitin sulfate supplemented with undenatured type 2 collagen, B vitamins, gingerol, and ascorbic acid

E. A. Strebkova; E. A. Taskina; N. G. Kashevarova; N. M. Savushkina; E. P. Sharapova; T. A. Korotkova; A. R. Khalmetova; D. M. Kudinsky; L. I. Alekseeva; A. M. Lila

doi:10.14412/1996-7012-2026-3-43-52

Approaches to therapy of the metabolic phenotype of osteoarthritis: efficacy of a combination of glucosamine and chondroitin sulfate supplemented with undenatured type 2 collagen, B vitamins, gingerol, and ascorbic acid

https://doi.org/10.14412/1996-7012-2026-3-43-52

Full Text:

PDF (Rus)

Generate QR code

Abstract

Objective: to evaluate the efficacy of the nutraceutical Teraflex Ultra, a combination of glucosamine (G, 1500 mg), chondroitin sulfate (CS, 1000 mg), undenatured type 2 collagen (UC-2, 40 mg), a B-vitamin complex, vitamin C (100 mg), and ginger root extract (300 mg), in patients with the metabolic phenotype of knee osteoarthritis (OA).

Material and methods. This prospective randomized study included 29 women aged 40–75 years with a definite diagnosis of knee OA stage I–III according to Kellgren–Lawrence (established in accordance with the ACR classification criteria) and metabolic syndrome, pain on walking ≥40 mm on the visual analog scale (VAS), who provided informed consent. Mean age was 62.4±6.9 years. Median baseline VAS pain was 63 [54; 75] mm. All patients received the nutraceutical Teraflex Ultra orally, 2 capsules twice daily for 6 months; the subsequent 3 months constituted the follow-up period with assessment of the carryover effect. Study duration was 9 months.

Results and discussion. The study results demonstrated a statistically significant clinical effect of the nutraceutical in patients with metabolic knee OA during the 6-month treatment course and the subsequent follow-up period. After 1 month of treatment, a significant (p<0.01) reduction in pain on walking in the analyzed knee according to VAS was observed; it persisted throughout the treatment period and 3 months after completion. A reduction of pain to <40 mm on VAS after 1 month of therapy was achieved in 48.3% of patients, after 3 months in 66.7%, and after 6 months in 81.5%. During follow-up, in most patients (77.7%) VAS pain remained <40 mm. Treatment was associated with significant improvement in all WOMAC parameters: decreased pain (baseline 246 [159; 320] mm; 1 month 173.5 [116; 199] mm; 3 months 119 [70; 186] mm; 6 months 84 [48; 157] mm; 9 months 73 [42; 106] mm; p<0.01 for all comparisons vs baseline); decreased stiffness (baseline 101 [63; 129] mm; 1 month 69.5 [36.5; 90] mm; 3 months 46 [23; 85] mm; 6 months 36 [19; 74] mm; 9 months 24 [15; 51] mm; p<0.01 for all comparisons vs baseline); decreased functional limitation (baseline 932 [610; 1085] mm; 1 month 660.5 [459; 767] mm; 3 months 463 [323; 748] mm; 6 months 309 [211; 559] mm; 9 months 265 [189; 440] mm; p<0.01 for all comparisons vs baseline). In all patients during the 6 months of treatment and the followup period, significant improvement in KOOS scores (p<0.01), quality of life according to EQ-5D, and patient global health assessment by VAS (p<0.01) was observed. As a result of therapy, most patients discontinued regular use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Conclusion. In patients with the metabolic phenotype of OA, the nutraceutical Teraflex Ultra (a combination of CS, G, UC-2, B vitamins, vitamin C, and ginger root extract) demonstrated a significant clinical effect accompanied by reduced pain, improved joint function and quality of life, and decreased need for NSAIDs.

Keywords

osteoarthritis, metabolic phenotype of osteoarthritis, chondroitin sulfate, glucosamine, undenatured type 2 collagen